TrialAnnals of oncology : official journal of the European Society for Medical Oncology2026

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

M D Galsky et al.PubMed ↗Publisher ↗

No numbers read from the abstract.